Want to see HK:0874 full AI Analyst Report?
Top Page
Guangzhou Baiyunshan Pharmaceutical Holdings Company
(0874)
Select Model
Select Model
Rating:59Neutral
Price Target:
HK$15.50
â–²(2.85% Upside)
Action:Reiterated
Date:08/24/26
The score is driven mainly by stable but weakening financial performance (profitability and balance sheet strength offset by sharp TTM revenue slowdown, margin/ROE compression, and uneven cash conversion). Weak technical signals weigh on near-term sentiment, while a reasonable P/E and high dividend yield provide valuation support.
Positive Factors
Diversified healthcare business model
Operations span pharmaceutical research, manufacturing, sales and healthcare-related distribution, creating multiple channels for scale and reducing reliance on a single product or activity over the medium term.
Negative Factors
Sharp recent revenue slowdown
The severe decline in the latest revenue run-rate raises questions about demand, product mix or operating continuity. Sustained weakness would limit scale benefits and make recovery in profitability more difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified healthcare business model
Operations span pharmaceutical research, manufacturing, sales and healthcare-related distribution, creating multiple channels for scale and reducing reliance on a single product or activity over the medium term.
Read all positive factors
Guangzhou Baiyunshan Pharmaceutical Holdings Company (0874) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$36.22B
Dividend Yield6.39%
Average Volume (3M)1.06M
Price to Earnings (P/E)12.8
Beta (1Y)0.69
Revenue Growth6.58%
EPS Growth-4.29%
CountryHK
Employees27,057
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)1.57
Shares Outstanding219,900,000
10 Day Avg. Volume1,951,667
30 Day Avg. Volume1,060,563
Financial Highlights & Ratios
PEG Ratio1.68
Price to Book (P/B)0.68
Price to Sales (P/S)0.33
P/FCF Ratio-27.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$20.70Price Target Upside37.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.94
Revenue Forecast (FY)HK$78.45B
Guangzhou Baiyunshan Pharmaceutical Holdings Company Business Overview & Revenue Model
Company Description
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GBPHCL) is a comprehensive pharmaceutical enterprise focused on the research, development, production, and distribution of a wide array of medical products. These offerings span traditi...
How the Company Makes Money
null...
Guangzhou Baiyunshan Pharmaceutical Holdings Company Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
68
Positive
Cash Flow
52
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 77.59B | 77.66B | 74.99B | 75.52B | 70.79B | 69.01B |
| Gross Profit | 11.86B | 12.52B | 12.52B | 14.19B | 13.28B | 13.23B |
| EBITDA | 3.69B | 3.95B | 4.90B | 6.49B | 6.22B | 5.82B |
| Net Income | 2.57B | 2.98B | 2.84B | 4.06B | 3.97B | 3.72B |
Balance Sheet | ||||||
| Total Assets | 87.81B | 84.55B | 81.68B | 78.59B | 74.67B | 66.12B |
| Cash, Cash Equivalents and Short-Term Investments | 25.66B | 23.81B | 22.72B | 21.31B | 22.56B | 22.38B |
| Total Debt | 19.54B | 20.70B | 12.37B | 11.70B | 11.43B | 9.92B |
| Total Liabilities | 45.25B | 43.40B | 43.91B | 41.91B | 41.03B | 34.79B |
| Stockholders Equity | 39.12B | 37.80B | 35.90B | 34.92B | 32.07B | 29.06B |
Cash Flow | ||||||
| Free Cash Flow | 2.16B | -954.34M | 2.31B | 2.48B | 5.62B | 4.42B |
| Operating Cash Flow | 3.43B | 253.50M | 3.44B | 4.10B | 7.00B | 5.67B |
| Investing Cash Flow | -3.07B | -3.81B | -5.96B | -3.11B | -7.25B | -931.57M |
| Financing Cash Flow | 1.30B | -98.13M | -1.01B | -1.98B | 45.95M | -1.49B |
Guangzhou Baiyunshan Pharmaceutical Holdings Company Technical Analysis
Negative
15.07
Price Trends
14.72
Negative
14.96
Negative
16.26
Negative
Market Momentum
-0.43
Positive
28.15
Positive
-3.05
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0874, the sentiment is Negative. The current price of 15.07 is above the 20-day moving average (MA) of 14.24, above the 50-day MA of 14.72, and below the 200-day MA of 16.26, indicating a bearish trend. The MACD of -0.43 indicates Positive momentum. The RSI at 28.15 is Positive, neither overbought nor oversold. The STOCH value of -3.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0874.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | HK$24.50B | 14.16 | 11.97% | 8.06% | -5.90% | -18.84% | |
68 Neutral | HK$27.86B | 5.91 | 7.92% | 5.40% | 7.94% | 52.83% | |
61 Neutral | HK$26.93B | 15.22 | 8.60% | 3.12% | 14.80% | -2.88% | |
60 Neutral | HK$17.43B | 15.32 | 6.61% | 3.44% | 7.35% | -45.49% | |
59 Neutral | HK$36.22B | 12.81 | 6.64% | 6.39% | 6.58% | -4.29% | |
59 Neutral | HK$64.20B | 17.45 | 6.97% | 2.78% | 9.88% | 9.30% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company
13.51
-4.07
-23.14%
HK:0867
China Medical System Holdings
11.04
-2.94
-21.02%
HK:1513
Livzon Pharmaceutical Group
20.38
-15.52
-43.23%
HK:2196
Shanghai Fosun Pharmaceutical (Group) Co
16.20
-9.54
-37.06%
HK:3320
China Resources Pharmaceutical Group Ltd.
4.44
-0.28
-5.98%
HK:0512
Grand Pharmaceutical Group Limited
4.91
-4.09
-45.43%
Guangzhou Baiyunshan Pharmaceutical Holdings Company Corporate Events
Baiyunshan Pharma Sets Mid-2026 Dividend in Unaudited Interim Report
Aug 21, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings has released a summary of its unaudited interim report for the six months ended 30 June 2026, prepared under China Accounting Standards for Business Enterprises. The board confirmed collective responsib...
Guangzhou Baiyunshan Declares 2026 Interim Dividend and Sets H Share Record Date
Aug 21, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings has declared a 2026 interim cash dividend of RMB0.30 per share for the six months ended 30 June 2026, following shareholder authorization at its 2025 AGM. The company will close its H share register fro...
Guangzhou Baiyunshan Pharma Announces 2026 Interim Dividend and Tax Treatment Details
Aug 21, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has declared an interim ordinary dividend of RMB 0.3 per share for the six months ended 30 June 2026, payable in Hong Kong dollars at HKD 0.3468 per share. The dividend relates to the fi...
Guangzhou Baiyunshan Schedules Board Meeting to Review 2026 Interim Results
Aug 10, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has scheduled a board meeting for 21 August 2026 to review and approve the unaudited financial results for the six months ended 30 June 2026. The meeting will also address any other busi...
Guangzhou Baiyunshan Pharma Calls August 2026 EGM to Vote on Board Pay
Aug 7, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings Company has called its first extraordinary general meeting of 2026 for 28 August in Guangzhou, convened by the board and open to H share investors recorded on the register that day. The company has set ...
Baiyunshan Unit Weighs Capital Raise to Bring In Strategic Investors
Jul 10, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has announced that its subsidiary Guangzhou Pharmaceuticals Company Limited plans to introduce strategic investors through a capital increase and share expansion process. GP Corp. intend...
Baiyunshan Pharma Sets Out Board Line-up and Committee Roles
May 29, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has announced the current composition of its board of directors, which includes six executive directors, one non-executive director and four independent non-executive directors, led by c...
Guangzhou Baiyunshan Sets Final 2025 Dividend and Tax Terms for H-Share Investors
May 29, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, a major player in the pharmaceutical and healthcare products sector, operates through H shares listed in Hong Kong and attracts a mix of mainland and overseas investors. Its business is...
Guangzhou Baiyunshan Shareholders Approve All AGM Resolutions and Board Changes
May 29, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited reported that its 2025 annual general meeting was held on 29 May 2026 in Guangzhou, with the session chaired by board chairman Li Xiaojun. The meeting was conducted in compliance with PR...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.